AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 16299322
Drug: Intramuscular injection
RxNorm normalized name: rabies, intramuscular injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular injection of MCP-CRM197 conjugate vaccine in alum
Trial: 7697308
Drug: Active administration
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active administration of specific bacterial cultures in fermented milk
Trial: 30975673
Drug: Urine CXCL10
RxNorm normalized name: Urin DS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Urine CXCL10 monitoring with study biopsy for subclinical rejection and treatment per protocol.
Trial: 22820612
Drug: Non-nucleoside reverse
RxNorm normalized name: Non-nucleoside reverse transcriptase inhibitors
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-nucleoside reverse transcriptase inhibitor-based regimen
Trial: 17227324
Drug: Oral medication
RxNorm normalized name: Oral Medication Syringe 3mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral medication treatment
Trial: 17227324
Drug: Diet only
RxNorm normalized name: phentermine hydrochloride Oral Capsule [T-Diet]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diet only treatment
Trial: 11722955
Drug: 14 mg
RxNorm normalized name: iodine 0.14 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 14 mg leucine x kg(‐1) x d(‐1)
Trial: 11722955
Drug: 22 mg
RxNorm normalized name: urea 0.22 MG/MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 22 mg leucine x kg(‐1) x d(‐1)
Trial: 11722955
Drug: 30 mg
RxNorm normalized name: agar 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mg leucine x kg(‐1) x d(‐1)
Trial: 11722955
Drug: 40 mg
RxNorm normalized name: rutin 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mg leucine x kg(‐1) x d(‐1)
Trial: 26696251
Drug: Single-dose rabbit
RxNorm normalized name: Rabbit
DrugBank: Rabbit (DB10415)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single-dose rabbit anti-thymocyte globulin (SD-rATG) 6 mg/kg
Trial: 26696251
Drug: Divided-dose rabbit
RxNorm normalized name: Rabbit
DrugBank: Rabbit (DB10415)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Divided-dose rabbit anti-thymocyte globulin (DD-rATG) 1.5 mg/kg/dose
Trial: 15684166
Drug: 100 microg
RxNorm normalized name: Digoxin 100 microgram oral capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 microg of sublingual misoprostol
Trial: 12851519
Drug: PL (equivalent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PL (equivalent to 100 mg isoflavone; n = 45)
Trial: 10566461
Drug: Online vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Online vaccine reminders
Trial: 9093647
Drug: Xylocaine 10%
RxNorm normalized name: Xylocaine 10% Oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Xylocaine 10% spray
Trial: 1910697
Drug: Topical lidocaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical lidocaine (4 mg/kg of 4% lidocaine)
Trial: 6293259
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of chemotherapy and irradiation
Trial: 6293259
Drug: Preoperative treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Preoperative treatment (irradiation)
Trial: 6293259
Drug: Patients operated
RxNorm normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients operated upon after preoperative treatment
Trial: 22313522
Drug: Lutein and
RxNorm normalized name: ICaps Lutein and Omega-3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lutein and zeaxanthin supplements (Study 2)
Trial: 22313522
Drug: Lutein and
RxNorm normalized name: ICaps Lutein and Omega-3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lutein and zeaxanthin supplements
Trial: 27704562
Drug: Raltegravir 1200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Raltegravir 1200 mg single oral dose
Trial: 27704562
Drug: Raltegravir 1200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Raltegravir 1200 mg co-administered with Efavirenz 600 mg
Trial: 24044461
Drug: Implants placed
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Implants placed 3 months after augmentation
Trial: 24044461
Drug: Implants placed
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Implants placed 6 months after augmentation
Trial: 19522571
Drug: Methylprednisolone 16
RxNorm normalized name: methylprednisolone 16 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methylprednisolone 16 mg/kg intravenously every day for 3 days
Trial: 18546838
Drug: Epithalamin pineal
RxNorm normalized name: Bos taurus pineal gland preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epithalamin pineal gland peptide medication
Trial: 15793365
Drug: Genotypic resistance
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Genotypic resistance testing alone (G arm)
Trial: 15793365
Drug: Genotypic plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Genotypic plus phenotypic testing (G + P arm)
Trial: 12418499
Drug: 1600 mg
RxNorm normalized name: glycerin 1600 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1600 mg SAMe/d orally for 6 weeks
Trial: 12418499
Drug: 400 mg
RxNorm normalized name: mesna 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 mg SAMe/d intramuscularly for 4 weeks
Trial: 12418499
Drug: 150 mg
RxNorm normalized name: pectin 150 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 150 mg imipramine/d orally
Trial: 10386277
Drug: Needle administration
RxNorm normalized name: NEEDLE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Needle administration
Trial: 6641536
Drug: 120 mg
RxNorm normalized name: papain 120 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 120 mg gentamycin intramuscularly
Trial: 6641536
Drug: 3 g
RxNorm normalized name: Molds 3 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 g amoxicillin orally
Trial: 30928207
Drug: Sham-rTMS (sham
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sham-rTMS (sham treatment)
Trial: 26362661
Drug: 20g SQ-LNS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20g SQ-LNS without zinc and 5mg zinc tablet
Trial: 26362661
Drug: 20g SQ-LNS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20g SQ-LNS without zinc and placebo tablet
Trial: 20848367
Drug: Oxygen cost
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxygen cost (mL O(2)/kg/m)
Trial: 17984403
Drug: Fluoxetine hydrochloride
RxNorm normalized name: Fluoxetine Hydrochloride
DrugBank: Fluoxetine (DB00472)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Fluoxetine hydrochloride (20 mg/d) with CBT
Trial: 15771764
Drug: LAM (lansoprazole
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LAM (lansoprazole 30 mg b.d., amoxicillin 1 g b.d., metronidazole 400 mg t.d.s.)
Trial: 15771764
Drug: LAC (lansoprazole
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LAC (lansoprazole 30 mg b.d., amoxicillin 1 g b.d., clarithromycin 500 mg b.d.)
Trial: 15771764
Drug: RMT (ranitidine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RMT (ranitidine bismuth citrate 400 mg b.d., metronidazole 400 mg t.d.s., tetracycline 500 mg q.d.s.)
Trial: 9617511
Drug: Lisuride (0.3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lisuride (0.3 mg daily for 12 weeks)
Trial: 3297874
Drug: Control (cytostatic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (cytostatic drugs and/or surgery without BCG)
Trial: 30358728
Drug: Daily oral
RxNorm normalized name: GEMTESA 75 MG Once-Daily Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily oral conjugated equine estrogens (0.625 mg/d)
Trial: 27457964
Drug: Orteronel 300
RxNorm normalized name: Orteronel
DrugBank: Orteronel (DB12066)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Orteronel 300 mg twice daily
Trial: 20133511
Drug: Oral treprostinil
RxNorm normalized name: Treprostinil
DrugBank: Treprostinil (DB00374)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Oral treprostinil 1 mg twice daily
Trial: 20133511
Drug: Bosentan 125
RxNorm normalized name: bosentan 125 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bosentan 125 mg twice daily
Trial: 20133511
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of oral treprostinil 1 mg twice daily and bosentan 125 mg twice daily
Trial: 18675689
Drug: H pylori
RxNorm normalized name: Helicobacter pylori
FDA approved: no
EMA approved: no
PMDA approved: no
Description: H pylori eradication regimen (lansoprazole 30 mg twice daily, amoxicillin 750 mg twice daily, and clarithromycin 200 mg twice daily for a week)
Trial: 18675689
Drug: Standard care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard care (no treatment for H pylori)
Trial: 18448418
Drug: Pregabalin 150
RxNorm normalized name: pregabalin 150 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pregabalin 150 mg (P150) with ibuprofen 800 mg
Trial: 18448418
Drug: Pregabalin 75
RxNorm normalized name: pregabalin 75 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pregabalin 75 mg (P75) with ibuprofen 800 mg
Trial: 18448418
Drug: Diazepam 5
RxNorm normalized name: diazepam 5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diazepam 5 mg (D5) with ibuprofen 800 mg
Trial: 15034644
Drug: Vitamin A
RxNorm normalized name: Vitamin A
DrugBank: Vitamin A (DB00162)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin A intake (0.53 mg/day)
Trial: 11399694
Drug: Active group
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active group (n = 36) participated in a 6-week program of education (2 h weekly) and exercise (1 h weekly)
Trial: 8369010
Drug: Ferro‐Folsan (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ferro‐Folsan (100 mg of ferrous‐II‐sulfate and 0.85 mg of folic acid)
Trial: 29771077
Drug: Flupentixol melitracen
RxNorm normalized name: melitracen
DrugBank: Melitracen (DB13384)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flupentixol melitracen (1 tablet/day) for 3 months
Trial: 24491199
Drug: Mindfulness treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mindfulness treatment group (MTG)
Trial: 22144668
Drug: Clopidogrel hydrogen
RxNorm normalized name: Clopidogrel hydrogen sulfate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clopidogrel hydrogen sulfate (CHS) 75 mg/d
Trial: 22144668
Drug: Clopidogrel besylate
RxNorm normalized name: Clopidogrel besylate
DrugBank: Clopidogrel (DB00758)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Clopidogrel besylate (CB) 75 mg/d
Trial: 17989536
Drug: Rapid protocols
RxNorm normalized name: Abreva Rapid Pain Relief
DrugBank: Glycerin (DB09462)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rapid protocols for venom immunotherapy
Trial: 17989536
Drug: Venom immunotherapy
RxNorm normalized name: bushmaster venom
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Venom immunotherapy in patients with mast cell diseases
Trial: 17989536
Drug: New strategies
FDA approved: no
EMA approved: no
PMDA approved: no
Description: New strategies for venom immunotherapy (genetic engineering)
Trial: 11259736
Drug: Oral glucose
RxNorm normalized name: glucose Oral Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral glucose loading (75 g) in pregnant women
Trial: 11259736
Drug: Oral glucose
RxNorm normalized name: glucose Oral Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral glucose loading (75 g) in non-pregnant women
Trial: 26632295
Drug: Local anesthesia
RxNorm normalized name: Esters of benzoic acid for local anesthesia
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Local anesthesia administered by students who practiced on the simulation model (experimental group, N=30)
Trial: 23945891
Drug: Acetazolamide (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acetazolamide (25 mg/kg/day) started in the first 48 hours after admission
Trial: 23945891
Drug: Acetazolamide (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acetazolamide (25 mg/kg/day) administered after the first 48 hours
Trial: 7264274
Drug: Topical diethylcarbamazine
RxNorm normalized name: diethylcarbamazine
DrugBank: Diethylcarbamazine (DB00711)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Topical diethylcarbamazine (DEC)
Trial: 7264274
Drug: Yeast tablets
RxNorm normalized name: Azo Yeast Tablets
DrugBank: Yeast (DB11017)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Yeast tablets
Trial: 28685204
Drug: Prasugrel (loading
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prasugrel (loading dose 20 mg, maintenance dose 3.75 mg/day for 7 days)
Trial: 28685204
Drug: Prasugrel (maintenance
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prasugrel (maintenance dose 3.75 mg/day for 7 days)
Trial: 28685204
Drug: Clopidogrel (75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clopidogrel (75 mg/day after switching from prasugrel)
Trial: 22520621
Drug: Resveratrol-rich grape
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Resveratrol-rich grape supplement (resveratrol 8 mg)
Trial: 22520621
Drug: Conventional grape
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional grape supplement lacking resveratrol
Trial: 19525871
Drug: L reuteri
RxNorm normalized name: L. reuteri
DrugBank: Lactobacillus reuteri (DB14224)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L reuteri (1 x 10 CFU)
Trial: 17544870
Drug: Sibutramine (15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sibutramine (15 mg/day for 12 weeks)
Trial: 11438377
Drug: Danazol (600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Danazol (600 mg daily for 6 months)
Trial: 11438377
Drug: Leuprorelin acetate
RxNorm normalized name: Leuprorelin acetate
DrugBank: Leuprolide (DB00007)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Leuprorelin acetate depot (3.75 mg every 28 days for 6 months)
Trial: 11438377
Drug: Post-treatment (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Post-treatment (3 months after termination of both treatments)
Trial: 9053474
Drug: Salvage treatments
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Salvage treatments after MOPP-ABVD
Trial: 9053474
Drug: Initial chemotherapy
RxNorm normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Initial chemotherapy re-treatment
Trial: 9053474
Drug: High-dose chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose chemotherapy or new regimens
Trial: 8429117
Drug: Placebo twice
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo twice daily (bid)
Trial: 30783676
Drug: TAK-003 (live-attenuated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TAK-003 (live-attenuated tetravalent dengue vaccine candidate)
Trial: 21289258
Drug: 60 mg
RxNorm normalized name: opium 60 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 60 mg denosumab every 6 months for 24 months
Trial: 21289258
Drug: Denosumab (after
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Denosumab (after discontinuation)
Trial: 21289258
Drug: Denosumab and
RxNorm normalized name: Denosumab
DrugBank: Denosumab (DB06643)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Denosumab and Placebo (off-treatment phase)
Trial: 16632297
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg zinc sulfate treatment
Trial: 14754691
Drug: 0.3 mg
RxNorm normalized name: biotin 0.3 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.3 mg synthetic conjugated estrogens
Trial: 14754691
Drug: 0.625 mg
RxNorm normalized name: estrone 0.625 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.625 mg synthetic conjugated estrogens
Trial: 14754691
Drug: 1.25 mg
RxNorm normalized name: menthol 1.25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.25 mg synthetic conjugated estrogens
Trial: 10910019
Drug: Selective adsorption
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Selective adsorption (SA) followed by intravenous immunoglobulin (i.v. IgG)
Trial: 10910019
Drug: Selective adsorption
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Selective adsorption (SA) using a tryptophan-linked polyvinyl alcohol gel adsorbent
Trial: 8112969
Drug: Oral pefloxacin
RxNorm normalized name: pefloxacin
DrugBank: Pefloxacin (DB00487)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral pefloxacin 400 mg
Trial: 30928413
Drug: Adjuvant chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvant chemotherapy (CAF [cyclophosphamide, doxorubicin, 5‐fluorouracil] vs. CMF [cyclophosphamide, methotrexate, 5‐fluorouracil])
Trial: 30928413
Drug: Tamoxifen treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tamoxifen treatment (subgroup analysis)
Trial: 25776729
Drug: Clonidine transdermal
RxNorm normalized name: Clonidine Transdermal System
DrugBank: Clonidine (DB00575)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Clonidine transdermal patch (test formulation)
Trial: 25776729
Drug: Clonidine transdermal
RxNorm normalized name: Clonidine Transdermal System
DrugBank: Clonidine (DB00575)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Clonidine transdermal patch (reference formulation)
Trial: 19114687
Drug: Radiotherapy (cumulative
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Radiotherapy (cumulative dose, 50 Gy)
Trial: 15080820
Drug: Fexofenadine (FEX)
RxNorm normalized name: fexofenadine Oral Tablet [Wal-Fex]
DrugBank: Fexofenadine (DB00950)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Fexofenadine (FEX) 180 mg once daily
Trial: 10835090
Drug: Corticosteroid treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Corticosteroid treatment (betamethasone)
Trial: 9258847
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of concentric and eccentric training (C‐E/‐E, n = 11)
Trial: 3522723
Drug: Single vaginal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single vaginal application of a suppository containing 10 mg of 9‐deoxo‐16‐PGE2
Trial: 22376226
Drug: Vision restoration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vision restoration therapy (VRT) combined with active tDCS
Trial: 22376226
Drug: Vision restoration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vision restoration therapy (VRT) paired with sham tDCS
Trial: 19581542
Drug: Xylitol topical
RxNorm normalized name: Xylitol
DrugBank: Xylitol (DB11195)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Xylitol topical oral syrup (2 xylitol [4.00-g] doses and 1 sorbitol dose) administered twice a day (Xyl-2x group)
Trial: 19581542
Drug: Xylitol topical
RxNorm normalized name: Xylitol
DrugBank: Xylitol (DB11195)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Xylitol topical oral syrup (3 xylitol [2.67-g] doses) administered thrice a day (Xyl-3x group)
Trial: 19581542
Drug: Control syrup
RxNorm normalized name: Afeditab CR
DrugBank: Nifedipine (DB01115)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Control syrup (1 xylitol [2.67-g] dose and 2 sorbitol doses)
Trial: 11815975
Drug: Treatment in
RxNorm normalized name: Other agents for local oral treatment in ATC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment in older cohorts (age > 70 years)
Trial: 6446314
Drug: Metronidazole 200
RxNorm normalized name: metronidazole 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metronidazole 200 mg twice daily
Trial: 6446314
Drug: Oxytetracycline 250
RxNorm normalized name: oxytetracycline 250 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxytetracycline 250 mg twice daily
Trial: 26863502
Drug: Continuous infusion
RxNorm normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous infusion (8 mL/h)
Trial: 26863502
Drug: Automated hourly
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Automated hourly boluses (8 mL/bolus)
Trial: 22407438
Drug: Adolescent-focused therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adolescent-focused therapy (AFT)
Trial: 17513814
Drug: Oral topotecan
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral topotecan 2.3 mg/m2/d on days 1 through 5 every 21 days
Trial: 17513814
Drug: IV topotecan
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV topotecan 1.5 mg/m2/d on days 1 through 5 every 21 days
Trial: 9520191
Drug: Topical 0.1%
RxNorm normalized name: adapalene topical 0.1% topical gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical 0.1% dexamethasone, polymyxin B (6,000 U/ml), and 0.5% neomycin 4 times a day for 1 week after RK or PRK
Trial: 9520191
Drug: Polymyxin B
RxNorm normalized name: Polymyxin B
DrugBank: Polymyxin B (DB00781)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Polymyxin B (6,000 U/ml) and 0.5% neomycin for 1 week after RK or PRK
Trial: 9520191
Drug: Topical 0.1%
RxNorm normalized name: adapalene topical 0.1% topical gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical 0.1% dexamethasone, polymyxin B (6,000 U/ml), and 0.5% neomycin 4 times a day for 15 days after LASIK
Trial: 2914543
Drug: Salsalate (1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Salsalate (1.5 g twice a day)
Trial: 2914543
Drug: Enteric-coated aspirin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enteric-coated aspirin (650 mg four times a day)
Trial: 29058298
Drug: Test formulation
RxNorm normalized name: mumps skin test antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Test formulation A
Trial: 29058298
Drug: Test formulation
RxNorm normalized name: mumps skin test antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Test formulation B
Trial: 19840530
Drug: Test dose
RxNorm normalized name: Epinephrine/Lidocaine Hydrochloride Epidural Kit [ANESTHESIA TRAY (W/TEST DOSE)]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Test dose + flush + 3-minute wait + EREM